Skip to main content
. 2019 Jan 29;10(1):e02687-18. doi: 10.1128/mBio.02687-18

FIG 3.

FIG 3

Experimental validation of selected 18 genes in cervical tissue samples. (A) Distribution of expression levels of 18 selected genes from the overlapped 614 gene transcripts, being measured by RNA-seq with RPKM. (B and C) TaqMan RT-qPCR validation of the 18 genes in 72 clinical cervical tissue samples, including 24 normal (N) cervix, 23 cervical cancer (CA), and 25 precancerous (CIN2 to CIN3) tissue samples. Experimental validation data of selective gene expression levels in human cervical samples are shown as mean ± SD log2 levels of cancer group versus normal group (B) or CIN2 to CIN3 group versus normal group (C). NS, not significant; *, P < 0.05; **, P < 0.01; ***, P < 0.001. (D) The expression of FAM83A, IQGAP3, and LY6K mRNAs was significantly increased along with the cervical lesion progression from CIN2 to CIN3 to cervical cancer compared to the normal cervical tissue samples. (E and F) Receiver operating characteristic (ROC) curves of the 18 gene transcripts, showing good discrimination in identifying cancer group versus CIN2-CIN3 plus normal group (E) or cancer group plus CIN2-CIN3 versus normal group (F). AKR1C2, aldo-keto reductase family 1 member C2; APOD, apolipoprotein D; ASF1B, anti-silencing function 1B histone chaperone; ASRGL1, asparaginase like 1; CDKN2A, cyclin-dependent kinase inhibitor 2A; CDT1, chromatin licensing and DNA replication factor 1; CELSR3, cadherin epidermal growth factor LAG seven-pass G-type receptor 3; CLDN10, claudin 10; CXCL5, C-X-C motif chemokine ligand 5; ELAVL2, ELAV-like RNA binding protein 2; FAM83A, family member with sequence similarity 83; FGFR3, fibroblast growth factor receptor 3; GRB7, growth factor receptor-bound protein 7; HSPB1, heat shock protein family B (small) member 1; IQGAP3, IQ motif containing GTPase-activating protein 3; KHSRP, KH-type splicing regulatory protein; KRT14, keratin 14; LY6K, lymphocyte antigen 6 family member K; MSX1, Msh homeobox 1; NOVA1, NOVA alternative splicing regulator 1; PROM1, prominin 1; PTBP1, polypyrimidine tract binding protein 1; RNASEH2A, RNase H2 subunit A; SDC1, syndecan 1; SEMA3F, semaphorin 3F; SLPI, secretory leukocyte peptidase inhibitor syndecan 1.